Arcus Biosciences (NYSE:RCUS) CAO Alexander Azoy Sells 4,343 Shares

Arcus Biosciences, Inc. (NYSE:RCUS) CAO Alexander Azoy sold 4,343 shares of the company’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $22.25, for a total transaction of $96,631.75. Following the completion of the transaction, the chief accounting officer directly owned 18,531 shares of the company’s stock, valued at approximately $412,314.75. The trade was a 18.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Alexander Azoy also recently made the following trade(s):

• On Wednesday, December 17th, Alexander Azoy sold 2,113 shares of Arcus Biosciences stock. The stock was sold at an average price of $22.16, for a total value of $46,824.08.
• On Tuesday, December 16th, Alexander Azoy sold 2,376 shares of Arcus Biosciences stock. The stock was sold at an average price of $21.88, for a total value of $51,986.88.
• On Wednesday, November 26th, Alexander Azoy sold 1,900 shares of Arcus Biosciences stock. The stock was sold at an average price of $26.00, for a total transaction of $49,400.00.
• On Monday, September 29th, Alexander Azoy sold 2,831 shares of Arcus Biosciences stock. The stock was sold at an average price of $13.00, for a total transaction of $36,803.00.

Arcus Biosciences Stock Performance

RCUS opened at $22.02 on Friday. The business’s 50-day simple moving average is $20.96 and its 200 day simple moving average is $14.04. Arcus Biosciences, Inc. has a 52-week low of $6.50 and a 52-week high of $26.40. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65. The firm has a market capitalization of $2.38 billion, a PE ratio of -6.40 and a beta of 0.75.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share for the quarter, topping the consensus estimate of ($1.33) by $0.06. The firm had revenue of $26.00 million for the quarter, compared to analyst estimates of $19.89 million. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The business’s quarterly revenue was down 45.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.00) EPS. As a group, sell-side analysts expect that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on RCUS shares. UBS Group reaffirmed a “buy” rating on shares of Arcus Biosciences in a research report on Monday. HC Wainwright raised their target price on shares of Arcus Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Citigroup reissued a “buy” rating on shares of Arcus Biosciences in a research report on Friday, December 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company raised their price target on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Monday, October 20th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Arcus Biosciences has an average rating of “Moderate Buy” and an average price target of $28.89.

Institutional Trading of Arcus Biosciences

A number of institutional investors have recently modified their holdings of the stock. Woodline Partners LP increased its holdings in Arcus Biosciences by 45.5% in the 1st quarter. Woodline Partners LP now owns 5,127,304 shares of the company’s stock valued at $40,249,000 after buying an additional 1,603,367 shares during the period. Vanguard Group Inc. raised its position in Arcus Biosciences by 24.1% during the first quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company’s stock valued at $52,499,000 after purchasing an additional 1,298,584 shares in the last quarter. RA Capital Management L.P. bought a new stake in Arcus Biosciences during the first quarter worth $8,920,000. Wellington Management Group LLP bought a new position in shares of Arcus Biosciences in the 1st quarter valued at $8,500,000. Finally, Bank of America Corp DE raised its holdings in shares of Arcus Biosciences by 173.5% during the 3rd quarter. Bank of America Corp DE now owns 1,360,781 shares of the company’s stock worth $18,507,000 after buying an additional 863,162 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.